BIOSECURE Act
Why China-relevant: biotechnology company of concern means— (A) BGI, MGI, Complete Genomics, Wuxi Apptec, and any subsidiary, parent affiliate, or successor of such entities ... The head of an executive agency may not— (1) procure or obtain any biotechnology equipment or service produced or provided by a biotechnology company of concern .
Path to becoming law
- Introduced
- Passed committee
- Passed House
- Passed Senate
- Sent to President
- Became law
done next step still ahead did not advance
Legislative timeline — dated actions so far
- Filed
Resolved. Model had estimated 3% to become law
- + Bipartisan support (6/10 cosponsors from across the aisle)
- + Broad cosponsorship (10 cosponsors)
- + Sponsored by a member of the majority party
Legislative likelihood — a tracking indicator, not investment advice.
Signals — secondary, directional
Directional context (see Methodology); the pinned, high-confidence axes are relevance and asset impact.
Shares that might be influenced
Each sector shows a direction (which way its China-related names are pushed) and, for precise mappings, how hard this bill hits the sector — rated marginal → very strong (1–5). Hover any chip for its definition. The headline 0–5 impact is at the top of the card.
Federal-procurement and contractor-use ban on named Chinese CRDMO/genomics firms (WuXi, BGI) that derive substantial revenue from US biopharma, with broad signaling/ripple effects on Chinese biotech equities
| Ticker | Name (Local) | Name (EN) | Restriction Lists |
|---|---|---|---|
| 688235.SS | 百济神州 | BEONE MEDICINES | |
| 600276.SS | 恒瑞医药 | HENGRUI PHARMA | |
| 603259.SS | 药明康德 | WuXi AppTec | |
| 3692.HK | 翰森制药 | Hansoh Pharmaceutical Group Company Limited | |
| 300760.SZ | 迈瑞医疗 | MR | |
| 2269.HK | 药明生物 | WUXI BIOLOGICS (CAYMAN) INC. | |
| 1801.HK | 信达生物 | Innovent Biologics, Inc. | |
| 6618.HK | 京东健康 | JD Health International Inc. | |
| 6990.HK | 科伦博泰生物 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | |
| 9926.HK | 康方生物 | Akeso,Inc. |